LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Inicio・Lista de Acciones・Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Cerrado

SectorSanidad

492.82 1.27

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

491.57

Máximo

495.72

Métricas clave
By Trading Economics
Ingresos	-314M 1.7B
Ventas	-1.2B 11B
P/B Media del Sector	24.631 50.102
BPA	5.44
Rentabilidad por dividendo	0.39
Margen de beneficios	15.048
Empleados	125,000
EBITDA	-905M 2.3B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+25.87% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	0.39% 2.33%
Próximas Ganancias	22 jul 2026
Fecha Próximo Dividendo	15 jul 2026
Próxima Fecha de Ex Dividendo	15 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-29B 167B
Apertura anterior	491.55
Cierre anterior	492.82

Noticias sobre sentimiento de mercado

By Acuity

35%

65%

96 / 344 Clasificación en Healthcare

Thermo Fisher Scientific Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 abr 2026, 13:56 UTC

Ganancias

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23 abr 2026, 10:28 UTC

Ganancias

Thermo Fisher Posts Higher 1Q Profit, Revenue

29 ene 2026, 11:34 UTC

Ganancias

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 oct 2025, 10:51 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 oct 2025, 20:49 UTC

Ganancias

Correction to Thermo Fisher Article on Oct. 22

22 oct 2025, 10:28 UTC

Ganancias

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

15 may 2026, 10:45 UTC

Charlas de Mercado

Contract Drug Manufacturers to Benefit From U.S. Pharma Onshoring Push -- Market Talk

23 abr 2026, 10:01 UTC

Ganancias

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23 abr 2026, 10:01 UTC

Ganancias

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23 abr 2026, 10:00 UTC

Ganancias

Thermo Fisher 1Q Net $1.65B >TMO

23 abr 2026, 10:00 UTC

Ganancias

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23 abr 2026, 10:00 UTC

Ganancias

Thermo Fisher 1Q EPS $4.43 >TMO

23 abr 2026, 10:00 UTC

Ganancias

Thermo Fisher 1Q Rev $11.01B >TMO

24 mar 2026, 12:04 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mar 2026, 12:00 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 ene 2026, 11:01 UTC

Ganancias

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q Net $1.96B >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q Rev $12.22B >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q EPS $5.21 >TMO

29 ene 2026, 11:00 UTC

Ganancias

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 oct 2025, 10:06 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 oct 2025, 10:05 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 oct 2025, 10:05 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 oct 2025, 10:04 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 oct 2025, 10:00 UTC

Adquisiciones, fusiones, absorciones

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 oct 2025, 10:01 UTC

Ganancias

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 oct 2025, 10:00 UTC

Ganancias

Thermo Fisher 3Q Rev $11.12B >TMO

Comparación entre iguales

Cambio de precio

Thermo Fisher Scientific Inc previsión

Precio Objetivo

By TipRanks

25.87% repunte

Estimación a 12 Meses

Media 613.27 USD 25.87%

Máximo 685 USD

Mínimo 490 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Thermo Fisher Scientific Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Thermo Fisher Scientific Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

96 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar